Evaluation of the Antiproliferative Effects of a Newly Synthesized Benzimidazole Compound on Prostate Cancer Cells

Design, synthesis, and nanomedicine based delivery of benzimidazole derivatives with promising antiproliferative activity.

These findings highlight benzimidazole derivatives, particularly 16a and 17b and their nanoparticle formulations, as promising anticancer candidates, driven primarily by strong cellular potency and favorable safety, substantiating their potential as lead candidates for further optimization and therapeutic development.

Design, synthesis, antiproliferative evaluation, and computational studies of novel quinoline–pyrazoline hybrids against breast and ovarian cancer cell lines

Among the synthesized compounds, PBc1 exhibited the greatest in vitro antiproliferative activity against both MDA-MB-231 and SK-OV-3 cell lines, suggesting that PBc1 is a promising compound for further biological and mechanistic investigation.

Synthesis, characterization, docking and in vitro evaluation of new pyrazole-carboxylate derivatives as antibacterial, anticancer and anti-inflammatory agents

Pyrazoles and chalcones have been extensively studied over time due to their broad range of therapeutic potentials. In this study, a new series of pyrazole-carboxylate derivatives were synthesized, characterized, and evaluated for their antibacterial, anticancer and anti-inflammatory activities. Among the synthesized derivatives, compound 5a exhibited significant percentage inhibition in colony counting assay. Compound 5c demonstrated significant cytotoxic activity with an IC50 value of 9.91 µg mL−1, while also exhibiting lower cytotoxicity towards non-cancerous HEK-293T cells (IC50 = 36.31 µg mL−1), indicating favourable selectivity. Mechanistic studies, including DAPI staining and flow cytometric analysis, indicated that compounds 5c and 5f inhibited cancer cell growth predominantly by inducing apoptosis rather than cell cycle arrest. Anti-inflammatory activity was determined using protein denaturation assay where compound 5f demonstrated promising activity with an IC50 value of 59.37 ± 0.149 µg mL−1. Furthermore, molecular docking analysis further provided insights into the binding interactions of the derivatives and the targeted protein. In addition, drug-likeness evaluation using swissADME indicates that the compounds satisfied Lipinski's rule of five.

Synthesis and Evaluation of Novel Piperazine Hybrids as Promising Anticancer Agents

The results revealed that the synthesised derivative 3h has potential binding affinity hence blocking the activity, and the synthesised piperazine derivatives are identified as promising lead compounds for further anticancer optimization.

Review of promising benzimidazole-based anticancer agents (2023-2026).

Structure–Activity Relationship and Cytotoxic Evaluation of Benzimidazole Derivatives as Potential Antileukemic Agents

Benzimidazole derivatives represent a versatile class of heterocyclic compounds with significant potential in anticancer drug discovery. In the present study, a series of benzimidazole analogues was synthesized via the modified Phillips condensation method and structurally characterized using FTIR, ¹H-NMR, ¹³C-NMR, mass spectrometry, and elemental analysis. The synthesized derivatives were evaluated for cytotoxic activity against HL60 (acute promyelocytic leukemia) and K562 (chronic myelogenous leukemia) cell lines using the MTT assay, with IC₅₀ values calculated through nonlinear regression analysis. Several compounds exhibited potent cytotoxic effects in the low micromolar range, with halogen-substituted derivatives such as 2-chloro and 5-bromo analogues showing IC₅₀ values below 6 μM. Selectivity indices confirmed preferential toxicity toward malignant cells compared to normal peripheral blood mononuclear cells. Structure–activity relationship analysis revealed that electronwithdrawing substituents, extended π-conjugation, and para-position halogenation significantly enhanced biological activity, while multiple hydroxyl substitutions reduced potency due to steric hindrance. Comparative evaluation with standard drugs demonstrated that while doxorubicin exhibited higher potency, benzimidazole derivatives offered better selectivity and broader applicability compared to imatinib. Statistical validation using ANOVA and logistic dose–response models confirmed the robustness of experimental findings. These results underscore the potential of benzimidazole derivatives as lead scaffolds for the development of novel antileukemic agents. Future directions include in vivo validation, molecular docking, and ADMET predictions to refine pharmacological profiles and facilitate clinical translation